It is the first antibody combination treatment authorised for use before exposure to COVID-19 infection in order to prevent disease licensed in the UK AstraZeneca (AZ) has announced that its antibody combination treatment Evusheld (tixagevimab co-packaged with cilgavimab) has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).
It is the first antibody combination for pre-exposure prophylaxis (PrEP) against COVID-19 to be licensed in the UK.
The treatment is authorised for use in adults who are not currently infected with
